Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)

Horizon Therapeutics plc today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of adults with chronic Thyroid Eye Disease... | May 1, 2023

Related Keywords

United States ,Japan ,Elizabethhz Thompson , ,Twitter ,Nasdaq ,Instagram ,Drug Administration ,Devices Agency ,Visa ,Japan Pharmaceuticals ,Facebook ,Linkedin ,European Group On Grave Orbitopathy ,Horizon Therapeutics ,Thyroid Eye Disease ,Medical Devices Agency ,Japan Registry ,Clinical Trials ,Inflammatory Bowel Disease ,Full Prescribing Information ,Thyroid Associated ,Grave Disease Is Mediated Through ,Insulin Like Growth Factor ,European Group ,Grave Orbitopathy ,Clinical Practice Guidelines ,Medical Management ,Horizon Therapeutics Public Limited Company Stock Exchange ,News ,Information ,Press Release ,Horizon ,Herapeutics ,Lc ,Oday ,Nnounced ,Hat ,The ,First ,Patient ,Gas ,Teen ,Unrolled ,N ,Hase ,Linical ,Trial ,Valuating ,Tepezza ,Or ,Treatment ,F ,Adults ,Ith ,Hronic ,Thyroid ,Ye Hznp Ie00bqpvqz61 ,